桂枝茯苓丸治疗原发性痛经的疗效:随机对照试验方案
本研究为随机双盲安慰剂对照试验方案,计划将符合条件的原发性痛经(热灼血瘀证)患者按1:1随机分入桂枝茯苓丸组与匹配安慰剂组,治疗3个月经周期并随访3个月。主要结局为视觉模拟量表(VAS)疼痛强度的平均变化,次要结局包括Cox月经症状量表、抑郁自评量表、焦虑自评量表及中医证候量表,并报告不良事件。
要点
- 桂枝茯苓丸治疗原发性痛经(热灼血瘀证)的随机双盲安慰剂对照试验方案。
- 治疗3个月经周期,随访3个月,主要结局为VAS疼痛强度平均变化。
- 次要结局包括CMSS、SDS、SAS及中医证候量表,并报告不良事件。
核心结论
- 该随机试验将是首个严格评估桂枝茯苓丸治疗热灼血瘀证原发性痛经疗效与安全性的研究。
- 研究结果将为未来桂枝茯苓丸用于原发性痛经提供客观临床依据。
研究设计与样本
- 随机、双盲、安慰剂对照试验。
- 符合条件的患者按1:1随机分入桂枝茯苓丸组与匹配安慰剂对照组。
- 治疗3个月经周期,随访3个月。
- 主要结局为视觉模拟量表(VAS)疼痛强度的平均变化。
- 次要结局包括Cox月经症状量表(CMSS)、抑郁自评量表(SDS)、焦虑自评量表(SAS)及中医证候量表,并报告不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary dysmenorrhea (PD) is one of the main gynecological complaints in women of child-bearing age, but limited effective treatments are available. Guizhi Fuling Wan (GFW), one of the most widely known traditional Chinese medicine (TCM) formulations, has been commonly used in clinical practice to treat gynecological disorders in China. In recent years, a growing number of studies have shown that GFW is beneficial for patients with PD. However, the quality of evidence is limited, and there are few studies on specific TCM syndromes of GFW for PD. Therefore, we plan to conduct a randomized controlled trial to explore the efficacy and safety of GFW for PD patients with heat-burning blood-stasis syndrome. METHODS AND ANALYSIS: The clinical study is a randomized, double-blinded, placebo-controlled trial. Eligible patients will be randomly assigned to the GFW group (treated with GFW) and the control group (treated with a matching placebo) in a 1:1 ratio for three menstrual cycles with a 3-month follow-up. The primary outcome will be the mean change of pain intensity measured by the visual analog scale (VAS). The secondary outcomes will include the Cox Menstrual Symptom Scale (CMSS), the Self-rating Depression Scale (SDS), the Self-rating Anxiety Scale (SAS), and the TCM syndrome scale. Adverse events will also be reported. DISCUSSION: This randomized trial will be the first rigorous study designed to assess the efficacy and safety of GFW in treating PD with heat-burning blood-stasis syndrome. The finding of this study will provide an objective clinical basis for the use of GFW for PD in the future. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000034118 . Registered on 24 June 2020.
引用
- Du Y, Li Y, Fu X, et al. Efficacy of Guizhi Fuling Wan for primary dysmenorrhea: protocol for a randomized controlled trial. Trials. 2021. PMID: 34922588. doi:10.1186/s13063-021-05834-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。